You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Golimumab for the treatment of psoriatic arthritis

  • Technology appraisal guidance
  • Reference number: TA220
  • Published:  27 April 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Psoriatic arthritis - golimumab: Manufacturer response to request for additional information from Merck Sharp & Dohme (formerly Schering-Plough)

Psoriatic arthritis - golimumab: Manufacturer response to request for additional information from Merck Sharp & Dohme (formerly Schering-Plough) Psoriatic arthritis - golimumab: Manufacturer response to request for additional information from Merck Sharp & Dohme (formerly Schering-Plough)
17 March 2011
(370.6 Kb 47 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 11 March 2011

Back to top